KRAS-IN-55
KRAS-IN-55 is a pan-KRAS inhibitor with IC50 values of 4.3, 9.6 and 1.6 nM against KRASG12C, KRASG12D and KRASG12V, respectively. KRAS-IN-55 induces the formation of a new binding pocket on KRAS, thereby forming a high-affinity ternary complex with cyclophilin A (CYPA), inhibiting the interactions of KRAS with downstream effectors RAF and PI3K, and blocking oncogenic MAPK and PI3K signaling pathways. KRAS-IN-55 is applicable to cancer research such as colorectal cancer and non-small cell lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C48H58FN9O5S
- Masse moléculaire:892.09
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
KRAS-IN-55 (Example 2) (72 h) inhibits the viability of KRASG12C, KRASG12D, and KRASG12V mutant cancer cells, with an IC50 of 15.2 nM in NCI-H358 cells, 10.5 nM in AGS cells, 2.8 nM in SW620 cells[1].
KRAS-IN-55 (0.0001-10 μM; 3 h) inhibits the interaction between KRASG12C, KRASG12D, KRASG12V and BRAFrbd, with an IC50 of 0.008 μM against KRASG12C, 0.044 μM against KRASG12D, and 0.010 μM against KRASG12V[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Masse moléculaire 892.09
-
Formule C48H58FN9O5S
-
SMILES
CCC1=[C@](N2CC(C)(COC([C@@H]3CCCN(C([C@H](CC4=NC(C5=C(C2=C1C=C5)F)=CS4)NC([C@H]6C[C@@H]6C7=CN=CC=C7)=O)=O)N3)=O)C)[C@]8=C(N=CC(N9CCN(CC9)C)=C8)[C@@H](OC)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)